VYNE Therapeutics (NASDAQ: VYNE) said its board authorized a 1-for-50 reverse stock split in connection with its merger with Yarrow Bioscience. – The merger is expected to close on or about July 24. – Following the merger, the combined company is expected to
VYNE Therapeutics Approves 1-for-50 Reverse Stock Split Ahead of Yarrow Merger
VYNE Therapeutics (NASDAQ: VYNE) said its board authorized a 1-for-50 reverse stock split in connection with its merger with Yarrow Bioscience. - The merger is expected to close on or about July 24. - Following the merger, the combined company is expected to